Natco Pharma Limited — PPTs, 23-07-2025: Investor Presentation

Here is the summary based on your preferences:

**Financial Highlights:**

NATCO Pharma proposes a ₹ 2,000 Cr investment for a 35.75% stake in South Africa’s Adcock Ingram. Adcock reported FY24 revenue of US$ 536 Mn, with 15% EBITDA and 8% net profit margins. NATCO will consolidate its proportionate share of profits.

**Strategic Initiatives & Growth Drivers:**

This investment expands NATCO's global footprint, utilizing South Africa as an African market gateway. Synergies include leveraging Adcock's network for NATCO product distribution, introducing affordable pharmaceuticals, and achieving cost/R&D efficiencies.

**Business Developments:**

NATCO Pharma plans to acquire a 35.75% stake in Adcock Ingram, a leading Southern African pharmaceutical company operating across Prescription, OTC, Hospital, and Consumer divisions.

**Market Position & Competitive Advantage:**

Adcock Ingram is the second-largest South African pharma by private market share, known for its strong brands. It uniquely covers all market segments: prescription, OTC, hospital, and consumer.

**Investor Implications:**

This strategic move offers positive growth potential, extending NATCO's reach into the African market. Value creation is expected from identified synergies and direct earnings contribution.